Castle Biosciences, Inc. (CSTL)
33.47
-0.73
(-2.13%)
USD |
NASDAQ |
Aug 24, 16:00
33.50
+0.03
(+0.09%)
After-Hours: 20:00
Castle Biosciences Debt to Equity Ratio : 0.078 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.078 |
| March 31, 2026 | 0.0796 |
| December 31, 2025 | 0.0786 |
| September 30, 2025 | 0.0795 |
| June 30, 2025 | 0.082 |
| March 31, 2025 | 0.0587 |
| December 31, 2024 | 0.058 |
| September 30, 2024 | 0.0606 |
| June 30, 2024 | 0.0594 |
| March 31, 2024 | 0.0622 |
| December 31, 2023 | 0.0391 |
| September 30, 2023 | 0.0377 |
| June 30, 2023 | 0.038 |
| March 31, 2023 | 0.0334 |
| December 31, 2022 | 0.0333 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.0327 |
| June 30, 2022 | 0.0182 |
| March 31, 2022 | 0.0199 |
| December 31, 2021 | 0.0196 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.1348 |
| June 30, 2020 | 0.157 |
| March 31, 2020 | 0.2882 |
| December 31, 2019 | 0.2952 |
| September 30, 2019 | 0.3025 |
| June 30, 2019 | -6.010 |
| March 31, 2019 | -6.551 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| RadNet, Inc. | 1.993 |
| Lumexa Imaging Holdings, Inc. | 1.586 |
| Labcorp Holdings, Inc. | 0.7861 |
| Quest Diagnostics, Inc. | 0.8493 |
| OPKO Health, Inc. | 0.3362 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 561.18M |
| Total Liabilities (Quarterly) | 91.15M |
| Shareholders Equity (Quarterly) | 470.03M |
| Current Ratio | 6.036 |
| Net Debt Paydown Yield | -0.30% |